Welcome to our dedicated page for Monte Rosa Therapeutics SEC filings (Ticker: GLUE), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Monte Rosa Therapeutics, Inc. (Nasdaq: GLUE) SEC filings page on Stock Titan provides access to the company’s regulatory disclosures as filed with the U.S. Securities and Exchange Commission. As a clinical-stage biotechnology company developing molecular glue degrader (MGD) medicines, Monte Rosa uses SEC reports to describe its clinical programs, collaborations, and financial condition.
Among the most informative documents for GLUE are current reports on Form 8-K, which the company uses to announce material events such as interim clinical data, financial results, and collaboration updates. For example, Monte Rosa has furnished 8-Ks summarizing positive interim Phase 1/2 data for MRT-2359 in metastatic castration-resistant prostate cancer and reporting quarterly financial results and business updates, including progress on MRT-8102, MRT-6160, and its partnerships with Novartis and Roche.
Investors can also reference Monte Rosa’s annual reports on Form 10-K and quarterly reports on Form 10-Q, which the company cites in its forward-looking statements as sources of detailed risk factors and operational information. These periodic filings typically include descriptions of the QuEEN™ discovery engine, the status of key programs such as MRT-8102, MRT-2359, and MRT-6160, and the structure of collaboration and license agreements.
On Stock Titan, GLUE filings are updated in near real time as they appear in the SEC’s EDGAR system. AI-powered tools help summarize lengthy documents, highlight key sections on clinical development, collaboration revenue, and cash runway, and make it easier to locate items on topics such as interim trial results, planned Phase 2 studies, or changes in capital structure. Users can quickly review Form 8-K disclosures about material events alongside the underlying press releases and presentations referenced in those filings.
New Enterprise Associates 17 and affiliates filed Amendment No. 3 to their Schedule 13D on Monte Rosa Therapeutics. They report beneficial ownership of 7,692,298 shares of common stock, representing 9.6% of the company based on 80,015,667 shares outstanding as of March 2, 2026.
The amendment states their ownership percentage has fallen by more than 1% solely because the number of Monte Rosa shares outstanding increased, and that no reporting person has traded in the last 60 days. NEA 17 holds the shares for investment purposes and the group outlines no current plans to change control, influence major corporate actions, or alter the issuer’s capital structure. Ali Behbahani also holds options to purchase 104,732 shares, bringing his calculated beneficial stake to 7,797,030 shares, or 9.7%.
Monte Rosa Therapeutics provides an in-depth overview of its business, risks, and drug pipeline focused on molecular glue degraders, or MGDs, in this annual report. The company remains pre-revenue from drug sales and highlights a history of significant operating losses with expectations of continued losses.
Monte Rosa is advancing three core clinical programs: MRT-6160 for immune-mediated diseases (out-licensed to Novartis), MRT-8102 for NLRP3/IL-1/IL-6-driven inflammatory diseases, and MRT-2359 for MYC-driven cancers such as metastatic castration-resistant prostate cancer. Early clinical data show deep target degradation, strong pharmacodynamic effects, and generally favorable safety profiles.
The company has entered major collaborations with Novartis and Roche that include substantial upfront payments and large potential milestone and royalty streams. As of June 30, 2025, the aggregate market value of common equity held by non-affiliates was $212 million, and 80,015,667 shares of common stock were outstanding as of March 2, 2026.
Monte Rosa Therapeutics reported fourth quarter and full-year 2025 results alongside major clinical and financing milestones. Collaboration revenue was $2.8 million in Q4 2025 versus $60.6 million a year earlier, and $123.7 million for 2025 versus $75.6 million in 2024. Full-year net loss improved to $38.6 million from $72.7 million despite higher R&D spending of $141.5 million.
Cash, cash equivalents, restricted cash and marketable securities were $382.1 million as of December 31, 2025. A follow-on equity offering in January 2026 raised approximately $345 million gross (about $323.8 million net), extending the company’s funding runway into 2029.
Clinically, NEK7-directed MGD MRT-8102 showed strong Phase 1 anti-inflammatory activity with CRP reductions of 85% and favorable safety in 88 treated participants, supporting multiple planned Phase 2 trials starting in 2026–2027. Oncology candidate MRT-2359 delivered a 100% PSA response rate in AR-mutant mCRPC patients in combination with enzalutamide, with a Phase 2 study with apalutamide planned for Q3 2026. Partnered VAV1-directed MGD MRT-6160 is progressing toward Novartis-led Phase 2 studies, backed by a collaboration that could yield up to $2.1 billion in milestones.
Monte Rosa Therapeutics Principal Accounting Officer Edmund Dunn reported an automatic sale of 139 shares of common stock. The shares were sold on March 4, 2026 at a price of $17.96 per share to cover tax withholding obligations triggered by the vesting of restricted stock units. According to the disclosure, these sales were automatic and not at Dunn’s discretion. After this tax-related transaction, he beneficially owned 22,554 shares of Monte Rosa Therapeutics common stock directly.
Monte Rosa Therapeutics President & CEO Markus Warmuth reported an open-market sale of 5,466 shares of common stock at a weighted average price of $17.9243 per share on March 2, 2026. The trades occurred between $17.50 and $18.46 under a pre-arranged Rule 10b5-1 trading plan adopted on May 14, 2025. After these transactions, he directly holds 613,471 shares of Monte Rosa Therapeutics common stock.
GLUE submitted a Rule 144 notice reporting proposed sales of its common stock traded on NASDAQ. The filing notes an RSU vest on 03/03/2026 tied to equity compensation and lists recent trades by Edmund Dunn: 1,039 shares on 01/05/2026 for $15,762.65, 25,164 shares on 02/27/2026 for $455,506.15, and 536 shares on 03/02/2026 for $9,380.
Monte Rosa Therapeutics principal accounting officer Edmund Dunn reported option exercises paired with share sales. On February 27 and March 2, 2026, he exercised stock options to acquire common shares at an exercise price of $13.41 per share.
He then sold a total of 25,700 common shares in open-market transactions, including a weighted-average sale price of $18.1015 per share for one block and $17.50 per share for another. After these trades, Dunn directly owned 22,693 Monte Rosa Therapeutics shares.
Form 144 filing reporting proposed sales and recent transactions by Markus Warmuth. The excerpt lists a proposed sale entry showing Common security lines and an RSU stock award granted 01/02/2025 with a related date 01/02/2026. The filing shows prior sales in the past three months with amounts 128372.00 and 153759.00 tied to Markus Warmuth, and an additional numeric line 97974.00 associated with a common security entry. The filing names Monte Rosa Therapeutics Inc and lists an address for Mr. Warmuth in Boston.
Morgan Stanley Smith Barney LLC Executive Financial Services filed a Form 144 disclosing the proposed sale of 536 common shares by means of a stock option exercise on 03/02/2026. The filing lists cash proceeds as the method of settlement.
The excerpt also reports recent open-market sales by Edmund Dunn of 25,164 shares for $455,506.15 on 02/27/2026 and 1,039 shares for $15,762.65 on 01/05/2026.
Issuer files a Form 144 reporting proposed sale of 25,164 common shares. The filing lists the transaction type as a Stock Option Exercise with a sale date of 02/27/2026. It also shows prior shares sold of 1,039 on 01/05/2026 for $15,762.65.